AXL receptor tyrosine kinase (also called tyrosine-protein kinase receptor UFO), a member of the tumor-associated macrophage (TAM) family of receptor tyrosine kinases (Rankin & Giaccia, 2016), is another emerging therapeutic target of IBC. AXL functions as an essential regulator of cancer cell growth, metastasis, angiogenesis, drug resistance, and immune invasion (Gjerdrum et al., 2010, Shen et al., 2022, Tanaka and Siemann, 2019, Wu et al., 2014), and the AXL pathway is overexpressed and